CNSX:TRUL

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. More Details


Snowflake Analysis

High growth potential with adequate balance sheet.


Similar Companies

Share Price & News

How has Trulieve Cannabis's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TRUL's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

2.0%

TRUL

-3.3%

CA Pharmaceuticals

-1.6%

CA Market


1 Year Return

124.2%

TRUL

-19.0%

CA Pharmaceuticals

-6.3%

CA Market

Return vs Industry: TRUL exceeded the Canadian Pharmaceuticals industry which returned -16.5% over the past year.

Return vs Market: TRUL exceeded the Canadian Market which returned -5.5% over the past year.


Shareholder returns

TRULIndustryMarket
7 Day2.0%-3.3%-1.6%
30 Day18.8%17.9%-0.8%
90 Day37.3%1.8%-0.7%
1 Year124.2%124.2%-19.0%-19.0%-2.9%-6.3%
3 Yearn/a-27.1%-27.9%3.4%-6.6%
5 Yearn/a168.4%166.7%31.6%11.4%

Price Volatility Vs. Market

How volatile is Trulieve Cannabis's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Trulieve Cannabis undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: TRUL (CA$31.21) is trading below our estimate of fair value (CA$94.63)

Significantly Below Fair Value: TRUL is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: TRUL is poor value based on its PE Ratio (20.8x) compared to the CA Pharmaceuticals industry average (20x).

PE vs Market: TRUL is poor value based on its PE Ratio (20.8x) compared to the Canadian market (16x).


Price to Earnings Growth Ratio

PEG Ratio: TRUL is good value based on its PEG Ratio (0.6x)


Price to Book Ratio

PB vs Industry: TRUL is overvalued based on its PB Ratio (8.5x) compared to the CA Pharmaceuticals industry average (1.4x).


Next Steps

Future Growth

How is Trulieve Cannabis forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?

37.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TRUL's forecast earnings growth (37.1% per year) is above the savings rate (1.7%).

Earnings vs Market: TRUL's earnings (37.1% per year) are forecast to grow faster than the Canadian market (22.8% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: TRUL's revenue (27% per year) is forecast to grow faster than the Canadian market (5.8% per year).

High Growth Revenue: TRUL's revenue (27% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if TRUL's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Trulieve Cannabis performed over the past 5 years?

84.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TRUL has a high level of non-cash earnings.

Growing Profit Margin: TRUL's current net profit margins (34.4%) are lower than last year (51.4%).


Past Earnings Growth Analysis

Earnings Trend: TRUL's earnings have grown significantly by 84.5% per year over the past 5 years.

Accelerating Growth: TRUL's earnings growth over the past year (47.1%) is below its 5-year average (84.5% per year).

Earnings vs Industry: TRUL earnings growth over the past year (47.1%) exceeded the Pharmaceuticals industry 30.9%.


Return on Equity

High ROE: TRUL's Return on Equity (40%) is considered high.


Next Steps

Financial Health

How is Trulieve Cannabis's financial position?


Financial Position Analysis

Short Term Liabilities: TRUL's short term assets ($413.7M) exceed its short term liabilities ($100.1M).

Long Term Liabilities: TRUL's short term assets ($413.7M) exceed its long term liabilities ($281.6M).


Debt to Equity History and Analysis

Debt Level: TRUL's debt to equity ratio (42.4%) is considered high.

Reducing Debt: Insufficient data to determine if TRUL's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: TRUL's debt is well covered by operating cash flow (61%).

Interest Coverage: TRUL's interest payments on its debt are well covered by EBIT (10.3x coverage).


Balance Sheet


Next Steps

Dividend

What is Trulieve Cannabis's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TRUL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TRUL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TRUL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TRUL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TRUL's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Kim Rivers (42 yo)

2.08yrs

Tenure

US$443,750

Compensation

Ms. Kimberly Rivers, also known as Kim, serves as Chairman of Trulieve Cannabis Corp. and has been its Chief Executive Officer and Director since September 2018 and November 2015 respectively. Ms. Rivers i ...


CEO Compensation Analysis

Compensation vs Market: Kim's total compensation ($USD443.75K) is below average for companies of similar size in the Canadian market ($USD3.02M).

Compensation vs Earnings: Kim's compensation has increased by more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Kimberly Rivers
CEO & Chairman2.08yrsUS$443.75k13.34%
$ 530.7m
Jason Pernell
Chief Information Officer2.08yrsUS$182.50k3.55%
$ 141.3m
Eric Raymond Powers
General Counsel & Corporate Secretary1.67yrsUS$209.17kno data
Kyle Landrum
Chief Production Officer1yrUS$653.36k0.0068%
$ 270.5k
Alex D'Amico
Chief Financial Officer0.33yrno data0.0012%
$ 46.9k
Lynn Ricci
Director of Investor Relations & Corporate Communications1.58yrsno datano data
Victoria Walker
Director of Marketing & Community Relationsno datano datano data
Timothy Morey
Chief Sales Officer1yrno datano data
Valda Coryat
Chief Marketing Officer0.83yrno datano data
Steven Ferrell
Director of Human Resources2.92yrsno data0.0068%
$ 270.5k
David Lummas
Chief of Staff0.25yrno datano data
Ryan Blust
Controller & Director of Financial Reportingno datano datano data

1.3yrs

Average Tenure

47yo

Average Age

Experienced Management: TRUL's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Kimberly Rivers
CEO & Chairman2.08yrsUS$443.75k13.34%
$ 530.7m
Peter Healy
Director1.25yrsno datano data
Susan Thronson
Director0.33yrno data0.0022%
$ 86.7k
Thomas Millner
Director0.33yrno datano data
Thad Beshears
Independent Director4.92yrsno data11.54%
$ 459.2m
George Hackney
Independent Director4.92yrsno data0.22%
$ 8.8m
Richard May
Independent Director4.92yrsno data0.35%
$ 14.0m
Michael O'Donnell
Independent Director2.33yrsno data0.016%
$ 624.1k

2.3yrs

Average Tenure

61.5yo

Average Age

Experienced Board: TRUL's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: TRUL insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12%.


Top Shareholders

Company Information

Trulieve Cannabis Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Trulieve Cannabis Corp.
  • Ticker: TRUL
  • Exchange: CNSX
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$3.978b
  • Shares outstanding: 127.45m
  • Website: https://www.trulieve.com

Number of Employees


Location

  • Trulieve Cannabis Corp.
  • 6749 Ben Bostic Road
  • Quincy
  • Florida
  • 32351
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TRULCNSX (Canadian National Stock Exchange)YesSubordinate Votings SharesCACADSep 2018
TCNN.FOTCPK (Pink Sheets LLC)YesSubordinate Votings SharesUSUSDSep 2018

Biography

Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded store ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/28 23:41
End of Day Share Price2020/10/28 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.